Unlock Exponential Candidate Design Iterations
Compare the safety, yield and expression of multiple AAV gene therapy candidates with different regulatory elements to pinpoint the highest-performing candidates aligned with clinical success criteria.
Request a Sample Report
Forecast the impact of switching AAV construct regions on cell titer and full capsids, enabling strategic comparisons and rankings.
Predict potential truncation propensities for forward and reverse strands when integrating different regulatory elements.
Identify top-performing candidates through an assessment of their truncation profile, secondary and tertiary structures, CpG island immunotoxicity and gene expression.
Harness in silico outcomes to identify promising construct combinations and sequence regions primed for significant performance enhancements.
Improve safety & yield by reducing truncation from secondary & tertiary structures
Maintain efficacy by reducing CpG islands without altering CG ratio
Reduce manufacturing trial and error with optimized full genome capsids
Fully understand constructs with automated AAV characterization reporting
Enhance constructs to generate de novo designs with the best predicted yield, efficacy and safety characteristics
Predict manufacturing results relating to truncations and other issues
